Altimmune, Inc. (ALT)
After hours:
- GlobeNewswire
Altimmune to Participate at Two Upcoming Investor Conferences
GAITHERSBURG, Md., May 07, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: JMP Life Sciences Conference (New York, NY)Tuesday, May 14, 2024Fireside Chat at 9:00 a.m. Eastern Time UBS Obesity Therapeutics Day (Virtual Conference)Thursday, May 23, 2024Fireside Chat at 10:00 a.m. Eastern Time The s
- GlobeNewswire
Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024
GAITHERSBURG, Md., May 02, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 and will provide a business update. Altimmune management will host a conference call at 8:30 am E.T. on May 9 to discuss financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.alti
- GlobeNewswire
Altimmune to Participate at Two Upcoming Conferences
GAITHERSBURG, Md., May 01, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr. Scott Harris, Chief Medical Officer at Altimmune, will present on behalf of the Company at the following two upcoming conferences: BTIG Obesity Health Forum (Virtual Conference)Title: Emerging Therapeutics PanelWednesday, May 8, 2024Panel Discussion at 4:00 pm Eastern Time GLP-1-Based Therapeutics Summit (Philadelphia, PA) Title: Focusing on the
